Johnson & Johnson has delivered a strong 28% total return year-to-date in 2026, outperforming major benchmarks like the S&P 500 ETF and healthcare sector ETF XLV. Despite solid second-quarter results and an upgraded full-year 2026 guidance driven by pharmaceutical momentum, the stock now trades at a premium valuation. Key risks include potential softness in MedTech growth, ongoing litigation challenges, and broader macroeconomic uncertainties. Technically, the stock remains in an uptrend but shows signs of possible near-term consolidation due to negative RSI divergence and high valuation, leading analysts to maintain a hold rating rather than recommending a buy or sell.
Five US-listed Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, Colgate-Palmolive, and Lowe's—have announced dividend increases and reported earnings reflecting resilience amid economic challenges like tariffs and currency swings. Johns...
Johnson & Johnson and AbbVie both posted strong quarterly results but differ in dividend approach and business focus. J&J, a Dividend King with 64 years of raises, offers a modest 2.02% yield supported by diversified pharma and MedTech products. AbbV...
The iShares Core High Dividend ETF (HDV) relies heavily on energy and pharmaceutical sectors, with Exxon Mobil, Chevron, Johnson & Johnson, and AbbVie making up about 26% of its assets. Exxon and Johnson & Johnson are rated very safe due to strong ca...
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
Invesco's High Yield Equity Dividend Achievers ETF (PEY) uses a unique strategy by selecting stocks with at least 10 years of consecutive dividend growth before filtering for high yield. This approach avoids the pitfalls of pure yield-based ETFs that...
